Biotech Stock News (ACAD) (RXII) (REGN) (AZN) (ZSPH)

Acadia Pharmaceuticals (NASDAQ:ACAD) On November 3, 2015 Acadia had announced that the FDA had given its Parkinson’s Drug, NUPLAZID, FDA priority review. To understand what this means, we must first understand what the FDA priority review actually means? A company is only given FDA priority review if the drug it has developed treats an unmet … Read more

Biotech Stock News (RXII) (REGN) (SURG) (VRX) (ACAD)

Rxi Pharmaceuticals (NASDAQ:RXII) On August 31, 2015 Rxi announced that the 30-day review period for its IND of RXI-109 for scarring of macular degeneration has passed its review period and the IND is now active. The whole point of the 30-day review period is for the FDA to look at pre-clinical data and conclude whether … Read more

Biotech Stock News (ISIS)(BAYRY)(ALXN)(GEVA)(LJPC)

Isis Pharmaceuticals (NASDAQ:ISIS) Shares of Isis were up 5% on May 4, 2015 after the company announced that Bayer AG (OTCMKTS:BAYRY) bought a license for an anti-clotting drug known as ISIS-FXRIx. This deal is more of a huge win for Isis as it continues to develop a multitude of RNA antisense drugs in many unmet … Read more

Biotech News 2/16/15 to 2/20/15

Oncolytics Biotech (ONCY) Shares of Oncolytics gained about 36% on 2/17/15 when it had announced that the company received FDA Orphan Drug Designation status for its pancreatic cancer drug Reolysin. Reolysin is a variant of the ReoVirus which occurs naturally in the environment. Oncolytics has engineered Reolysin to multiply at an alarming rate inside of … Read more